Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and ...

Steve Roth learned there might be something dangerous in his soil from a work crew behind his house. One day five years ago, he walked outside and found a group digging up dirt they said was ...

Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for ...

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

Despite decades of research, multiple myeloma remains an incurable disease. A wide array of therapies, such as proteasome ...

A study published in Nature shows that certain autoantibodies may influence how cancer patients respond to immunotherapy. Autoantibodies are proteins produced by the immune system and have typically ...